Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Wedbush Reiterates Outperform on Gossamer Bio, Maintains $6 Price Target

Author: Benzinga Newsdesk | December 19, 2023 09:39am
Wedbush analyst Andreas Argyrides reiterates Gossamer Bio (NASDAQ:GOSS) with a Outperform and maintains $6 price target.

Posted In: GOSS

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist